Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sangamo Looks Forward After Shire Returns Hemophilia Rights

This article was originally published in Scrip

Executive Summary

Sangamo Biosciences touted the progress of its in vivo protein replacement platform (IVPRP) as it reported that Shire relinquished its rights to hemophilia programs under the companies' three-year-old collaboration, but investors were wary about the loss of an important alliance for two out or four partnered programs as well as the exchange of milestone fees for total control of preclinical assets.

Advertisement

Related Content

Biogen Shores Up Gene Therapy Ambitions With New Deal

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC029665

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel